Humanin vs Pinealon
Both Humanin and Pinealon are used for longevity. Here's how their evidence, dosing, and regulatory status actually compare.
Humanin
Evidence BHumanin (HN)
A 24-amino-acid mitochondrial-derived peptide with cytoprotective effects across Alzheimer's, diabetes, and atherosclerosis preclinical models. Endogenous levels decline sharply with age.
View full Humanin profile →Pinealon
Evidence CPinealon (EDR)
A short tripeptide developed in Russia for cognitive aging and oxidative stress. Limited Western clinical evidence.
View full Pinealon profile →Side-by-Side
| Attribute | Humanin | Pinealon |
|---|---|---|
| Evidence Grade | B | C |
| FDA Status | Not FDA-approved — mitochondrial-derived peptide research compound | Not FDA-approved — Russian-origin research peptide |
| Typical Dose | Research range: 0.5–1 mg subcutaneous (rare clinical use) | 5–10 mg daily for 10–20 days (subcutaneous, cycled) |
| Clinics Indexed | 5 | 9 |
| Categories | mitochondrial, longevity, neuroprotection | cognitive, longevity |
Key reported benefits — Humanin
- ✓Cytoprotection
- ✓Anti-amyloid effects
- ✓Insulin sensitization
Key reported benefits — Pinealon
- ✓Cognitive function (preclinical)
- ✓Reduced oxidative damage
- ✓Sleep/circadian effects
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.